blog counter

Avid Radiopharmaceuticals
Biotech Specialty Pharma
3624 Market Street, 5th Floor
Philadelphia, PA 19104 USA
phone: 215-966-6208
fax:
Symbol Private
Founded 0
Employees
www.avidrp.com
Research Sector Biotech Specialty Pharma
Summary Description
Radiopharmaceuticals for imaging Alzheimer's disease pathology.
Management
Daniel M. Skovronsky, M.D., Ph.D., Founder and CEO; Alan P. Carpenter, Jr., Ph.D., J.D., Vice President, Business Development and Legal Affairs; Franz F Hefti, PhD Vice President, Neuroscience; Rajesh Manchanda, Ph.D., Vice President, Product Development; Michael Pontecorvo, Ph.D., Vice President, Clinical Development
Keywords
radiopharmaceuticals, imaging, alzheimer's, in vivo, amyloid, plaques, emission, computed, tomography, pet, photon, spect, diagnostics, personalized
http://www.avidrp.com/images/logo_avid.gif

Comment | Printable Version | Dec. 17, 2007
If you work for Avid Radiopharmaceuticals and want to update this profile, click here


Description
Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging Alzheimer's disease pathology.
Products / Services
Two of Avid's radiopharmaceuticals are already in clinical trials, and Avid intends to make these products available to pharmaceutical companies that are seeking to develop new drugs for treatment of Alzheimer's disease. By providing a readily measured biomarker for this disease, Avid's products can facilitate testing of therapies aimed at amyloid plaques. Avid's first commercial product for the Alzheimer's diagnostic market is ready for development and will be used for positron emission tomography (PET).
Technology / Differentiation
Avid's Alzheimer's disease program is based on the hypothesis that in vivo detection of amyloid plaques by positron emission computed tomography (PET) or single photon emission computed tomography (SPECT) imaging would provide useful biomarkers for monitoring and diagnosis of Alzheimer's disease. To test this hypothesis, we have developed novel radiolabeled compounds that specifically and sensitively bind A b (the chief constituent of amyloid plaques), and are testing these compounds as molecular imaging agents in preclinical and clinical trials.